Preexposure prophylaxis (PrEP), coformulated as tenofovir (TFV), disoproxil fumarate (TDF), and emtricitabine (FTC), is a biomedical intervention that has demonstrated a reduction of human immunodeficiency virus (HIV) transmission rates by as much as 75% in heterosexual serodiscordant partnerships and up to 99% among men having sex with men (MSM) and transgender women when taken daily.1,2 It was approved by the US Food and Drug Administration in 2012 for adults 18 years and older, but approval for adolescents younger than 18 years has stalled because of limited data on the efficacy, acceptability, and safety among adolescents younger than 18 years.
Arrington-Sanders R. Human Immunodeficiency Virus Preexposure Prophylaxis for Adolescent MenHow Do We Ensure Health Equity for At-Risk Young Men?. JAMA Pediatr. Published online September 05, 2017. doi:10.1001/jamapediatrics.2017.2397
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.